Your session is about to expire
← Back to Search
Targeted Therapy for Advanced Cancer (MyTACTIC Trial)
MyTACTIC Trial Summary
This trial will test new targeted therapies for safety and efficacy in patients with advanced, unresectable solid tumors. Patients will be enrolled based on the presence of specific biomarkers, and will be treated with a drug or drug regimen tailored to their individual biomarker profile.
MyTACTIC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMyTACTIC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MyTACTIC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have HIV, HCV, or HBV infections that meet the study criteria.I meet the specific requirements for my chosen treatment option.I had a precise radiation treatment within the last week.My brain metastases are stable and not causing symptoms.I do not have any serious health issues that would make it unsafe for me to join the study.My test results, from a certified lab, show a positive biomarker.I haven't had any cancer other than my current type in the last 3 years.I meet the specific requirements for my chosen treatment option.I haven't had major surgery or significant injury in the last 4 weeks and don't expect to need major surgery during the study.My blood and organ tests meet the study's requirements.I have not had wide field radiotherapy in the last 14 days.I haven't had a severe infection or been hospitalized for one in the last 4 weeks.My cancer is advanced, cannot be surgically removed, and has spread.I have had leptomeningeal disease.I haven't taken any cancer drugs or experimental treatments in the last 21 days, except hormone therapy.I am fully recovered from any past surgeries before starting the study treatment.I do not have serious heart issues like recent heart attacks or unstable heart rhythms.I can take care of myself and am up and about more than half of my waking hours.
- Group 1: Arm H: PH FDC SC + Investigator's Choice of Chemotherapy
- Group 2: Arm I: Trastuzumab Emtansine + Tucatinib
- Group 3: Arm F: Trastuzumab Emtansine + Atezolizumab
- Group 4: Arm N: Atezolizumab + Tiragolumab
- Group 5: Arm E: Atezolizumab + Investigator's Choice of Chemotherapy
- Group 6: Arm M: Ipatasertib + Paclitaxel
- Group 7: Arm J: Trastuzumab Emtansine + Atezolizumab
- Group 8: Arm L: Ipatasertib + Atezolizumab
- Group 9: Arm O: Pralsetinib
- Group 10: Arm D: Ipatasertib
- Group 11: Arm G: PH FDC SC
- Group 12: Arm K: Ipatasertib + Atezolizumab
- Group 13: Arm A: Entrectinib
- Group 14: Arm B: Inavolisib
- Group 15: Arm C: Alectinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide me with a summary of any supplemental research related to Tiragolumab?
"Tiragolumab was first researched back in 1997 at the City of Hope Comprehensive Cancer Center. At present, a total of 1580 clinical trials have been finished, with 1352 ongoing across numerous locations - primarily Modesto, California."
Are recruitment efforts underway to include participants in this experiment?
"Data sourced from clinicaltrials.gov indicates that this medical trial is not presently seeking new candidates, despite having been posted initially on January 13th 2021 and last updated on September 8th 2022. With 3,732 other trials recruiting participants at present, however, there are plenty of opportunities available for those interested in taking part in a clinical study."
How many medical institutions are conducting this trial currently?
"46 medical centres across the United States are presently enrolling patients for this trial. Major cities that are included in these locations include Modesto, Boise and Sacramento; however, there is a plethora of other sites to choose from closer to home if you opt-in."
To what maladies is Tiragolumab typically applied?
"Tiragolumab is frequently used to mitigate metastatic bladder cancer, as well as inflammatory breast cancer (IBC), small cell lung cancer (SCLC) and other malignant neoplasms."
How many participants is the maximum capacity for this clinical trial?
"Sadly, this trial is no longer recruiting. It was first introduced on the 13th of January 2021 and last updated on 8th September 2022. If you are researching other trials, there are 2380 studies reliant upon cancer patients and another 1352 for Tiragolumab that still need participants."
Has Tiragolumab been accepted by the FDA for use in treatments?
"Despite there being no evidence of its efficacy, the safety profile of Tiragolumab has been assessed to be a 2 due to some preliminary data."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger